Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Yahoo/BusinessWire
Incyte's Jakafi Is Likely A $1 Billion Drug
Seeking Alpha
Incyte looks to ride on drug's success
The News Journal, DE
YM Biosciences: The Next Way To Get Long Myelofibrosis
Seeking Alpha
Is YM the Next Incyte?
Minyanville
YM Bio's Myelofibrosis Drug Is For Real
TheStreet.com
Incyte CEO Touts Prospects of New Cancer Drug
Minyanville
F.D.A. Approves Drug for Bone Marrow Disease
NY Times, NY
The Big Bet on YM BioSciences
Motley Fool